CC‐292 is the first irreversible BTK inhibitor that has been evaluated in a Phase II study. Forty‐seven patients with active RA who had an inadequate response to methotrexate were randomized to receive either CC‐292 375 mg daily or a placebo. The gene discussed is BTK; the disease is rheumatoid arthritis.